Drug intelligence / Profile preview

glasdegib + temozolomide

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Glasdegib + temozolomide is an investigational combination therapy that pairs glasdegib, a potent inhibitor of the Hedgehog signaling pathway, with temozolomide, an alkylating agent. Glasdegib enhances chemosensitivity by inhibiting the Hedgehog pathway, which may increase the effectiveness of temozolomide's DNA-damaging effects in cancer cells. This combination has been studied primarily for the treatment of glioblastoma.

Targets

SMO (Smoothened)DNA

Beyond the preview

Go deeper on glasdegib + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on glasdegib + temozolomide.

Explore the full profile